Quilliot D, Petit F X, Cornette A, Ziegler O
Service de Diabétologie, Maladies Métaboliques et Nutrition, Centre Hospitalier Universitaire de Nancy, Hôpital Jeanne-d'Arc, 54200 Dommartin-lès-Toul, France.
Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 2):S38-51.
Obesity is known to predispose to obstructive sleep apnea (OSA), a condition characterized by repeated episodes of apnea or hypopnea during sleep, due to the interruption of airflow through the nose and mouth. These episodes lead to the fragmentation of sleep and to decrease in oxyhaemoglobin saturation. Patients with massive obesity, with or without daytime hypersomnolence should be systematically screened for OSA, because many of them appear to be asymptomatic and unaware of their breathing abnormalities during sleep. Polysomnography (PSG) in an attended hospital laboratory setting is the gold standard for the diagnosis of OSA. However portable recording devices can be used for screening with good sensibility and specificity, and even for diagnosis when the apnea-hypopnea index is high. However the final diagnosis can only be carried out in a sleep laboratory using PSG by highly-qualified personnel, because of the limitations of the portable recording device. There is a strong association between OSA and the risk of traffic accidents. It has been established that OSA affects quality of life. There is also increasing evidence that OSA is an independent risk factor for cardio-vascular diseases. This has been successfully demonstrated for hypertension by prospective studies. But the evidence remains weak for myocardial infarction, stroke or mortality. Treating OSA with continuous positive airway pressure (CPAP) is the treatment of choice. CPAP improves quality of life, driving simulator performance, blood pressure and sleepiness, as demonstrated by randomised placebo controlled trials. The majority of obese OSA patients are currently not being offered diagnosis testing and treatment. It's a real challenge due to the epidemic increase of obesity prevalence. Portable recording devices could be available outside the sleep laboratory in nutrition department, where morbid obesity is treated. This emphasizes the need for a real collaboration between these departments and sleep experts.
众所周知,肥胖易引发阻塞性睡眠呼吸暂停(OSA),这是一种在睡眠期间因鼻腔和口腔气流中断而反复出现呼吸暂停或呼吸不足的病症。这些发作会导致睡眠碎片化,并使氧合血红蛋白饱和度降低。对于患有严重肥胖症的患者,无论有无日间嗜睡症状,都应系统地筛查OSA,因为他们中的许多人似乎没有症状,且未意识到自己睡眠期间的呼吸异常。在医院实验室进行的多导睡眠图(PSG)检查是诊断OSA的金标准。然而,便携式记录设备可用于筛查,其敏感性和特异性良好,当呼吸暂停低通气指数较高时甚至可用于诊断。然而,由于便携式记录设备的局限性,最终诊断只能由高素质人员在睡眠实验室使用PSG进行。OSA与交通事故风险之间存在密切关联。已经证实OSA会影响生活质量。也有越来越多的证据表明OSA是心血管疾病的独立危险因素。前瞻性研究已成功证明其与高血压有关。但对于心肌梗死、中风或死亡率,证据仍然不足。持续气道正压通气(CPAP)治疗是OSA的首选治疗方法。随机安慰剂对照试验表明,CPAP可改善生活质量以及驾驶模拟器表现、血压和嗜睡情况。目前,大多数肥胖的OSA患者未接受诊断测试和治疗。鉴于肥胖患病率的流行增长,这是一个真正的挑战。便携式记录设备可在营养科等睡眠实验室之外的地方使用,营养科是治疗病态肥胖症的地方。这强调了这些科室与睡眠专家之间进行真正合作的必要性。